RNA Interference Therapeutics
33 places
Worldwide report
Every place
- 33Reports naming them
- 1Markets they lead in
- 33Regions & countries
- 3Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by Dicerna (Novo Nordisk) or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Where they show up
33 reportsOur reports that name Dicerna (Novo Nordisk) as a key player, by category and place.
- Pharmaceuticals · 33
Places 33
- Africa 1
- APAC 1
- Australia 1
- Brazil 1
- Canada 1
- China 1
- Ecuador 1
- Egypt 1
- Europe 1
France 1- Germany 1
- Global 1
Hong Kong 1
India 1
Italy 1
Japan 1
Kenya 1- Latin America 1
Malaysia 1
Mexico 1- Middle East 1
New Zealand 1- North America 1
Philippines 1
Russia 1
Saudi Arabia 1
Singapore 1
South Africa 1
Spain 1
Thailand 1- UAE 1
UK 1
US 1
Dicerna (Novo Nordisk)'s markets
1Markets where they are a key player. Each opens the market's statistics for every place we cover.
Pharmaceuticals1
None of their markets match.
Recent reports naming Dicerna (Novo Nordisk)
Our newest markets with them as a key player. Each covers 2024 history, a 2025 base year and forecasts to 2034.
33 places
Companies they compete with most
Named as key players in the same markets as Dicerna (Novo Nordisk) (number of shared markets).
Alnylam Pharmaceuticals1 shared market
Arrowhead Pharmaceuticals1 shared market
Ionis Pharmaceuticals1 shared market
Novartis AG1 shared market
Novartis AG1 shared market
Free public data on Dicerna (Novo Nordisk)
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Clinical trials
3 active studies led by Dicerna (Novo Nordisk), of 18 in all
Source: ClinicalTrials.gov, Studies with Dicerna (Novo Nordisk) (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Trials over time
Studies Dicerna (Novo Nordisk) leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with Dicerna (Novo Nordisk) or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Topics
The topics of the markets Dicerna (Novo Nordisk) is in.
From our blog
Stories on the topics Dicerna (Novo Nordisk) works in.
Patient Support Programmes: Helping Patients Stay on Treatment
WHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient…
Read
Biologic Safety Testing: The Quiet Backbone of Drug Making
Every vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches…
Read
Cell-Based Immunotherapy: Promise and Price
The first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
Read